Please ensure Javascript is enabled for purposes of website accessibility

LabCorp Launches New Coronavirus Antibody Test

By Cory Renauer – Jun 25, 2020 at 3:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The diagnostics industry leader's PhenoSense assay will also gauge how well a patient's antibodies will fare in fighting off SAR-CoV-2.

LabCorp (LH -1.53%) on Thursday launched a new coronavirus blood test with a twist -- instead of simply looking for antibodies produced by the immune system in response to SARS-CoV-2, the PhenoSense assay will also assess the antibodies it finds for their capacity to inhibit the coronavirus that causes COVID-19.

Antibodies that better-neutralize SARS-CoV-2

As one of the largest laboratory service providers in the U.S., LabCorp has access to lots of specimens from patients who have recovered from COVID-19. The company's been building its COVID-19 RECOVER biobank with samples collected after patients' first positive tests. 

Filling laboratory sample tubes.

Image source: Getty Images.

LabCorp has been combining information regarding the antibodies found in COVID-19 patient blood samples processed at its 2,000-plus service locations spread throughout the U.S. By combing through data from patients with varying degrees of symptom duration and severity, the company has built a useful tool for vaccine and drug developers.

In addition to the biopharmaceutical industry, LabCorp intends to make the PhenoSense assay available to hospitals, blood banks, and other plasma-screening facilities.

Convalescent plasma

Using blood plasma from a recovered patient to treat another with the same infectious disease is an old practice that has the potential to become much more effective. Instead of simply transferring plasma from a recovered patient to one more recently infected and hoping for the best, physicians can screen potential donors with LabCorp's PhenoSense test to raise their procedure's chance of success.

An antibody screening tool isn't the only step LabCorp's taking to address the pandemic. Earlier this month, LabCorp created a service to connect people -- specifically, those currently suffering from COVID-19, those who have recovered, and those worried about potential exposure -- with clinical trials run by its drug development business, Covance.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Laboratory Corporation of America Holdings Stock Quote
Laboratory Corporation of America Holdings
LH
$204.81 (-1.53%) $-3.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.